ALLAN LIPTON
Medical Practice in Swatara, PA

License number

Pennsylvania MD012841E

Personal information

See more information about ALLAN LIPTON at radaris.com

Name

Address

Phone

Allan Lipton, age 85

105 Woodbine Dr, Hershey, PA 17033

(717) 533-2128

Allan Lipton

Hershey, PA

(717) 533-2128

Allan Lipton

500 University Mnr, Hershey, PA 17033

(717) 531-6955

Allan L Lipton

105 Woodbine Dr, Hershey, PA 17033

(717) 533-2128

Professional information

See more information about ALLAN LIPTON at trustoria.com

Allan Lipton, Hershey PA

Work:

Milton S. Hershey Medical Center
500 University Dr, Hershey, PA 17033

Dr. Allan Lipton, Hershey PA - MD (Doctor of Medicine)

Specialties:

Oncology, Medical Oncology

Address:

Penn State Hematology Oncology
500 University Dr SUITE 4425, Hershey 17033
(717) 531-6585 (Phone)

Certifications:

Internal Medicine, 1970, Medical Oncology, 1973

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
New York University
Graduated: 1963
Cornell U-Bellevue Hosp
Memorial Sloan-Kettering Cancer Center
Salk Inst Biological Studie

Allan Lipton, Hershey PA

Specialties:

Oncologist

Address:

500 University Dr, Hershey, PA 17033

Education:

New York University, School of Medicine - Doctor of Medicine
Memorial Sloan-Kettering Cancer Center - Residency - Oncology (Internal Medicine)
Memorial Sloan-Kettering Cancer Center - Residency - Hematology
New York Presbyterian Hospital/Weill Cornell Medical Center - Residency - Family Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)

Oligonucleotide Inhibition Of Epidermal Growth Factor Receptor Expression

US Patent:

5914269, Jun 22, 1999

Filed:

Apr 4, 1997

Appl. No.:

8/832658

Inventors:

C. Frank Bennett - Carlsbad CA
Allan Lipton - Hershey PA
Lois M. Witters - York Haven PA

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA
The Penn State Research Foundation - University Park PA

International Classification:

C07H 2104, A61K 4800

US Classification:

435375

Abstract:

Compounds, compositions and methods are provided for inhibiting the expression of human EGFR. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding EGFR. Methods of using these oligonucleotides for inhibition of EGFR expression and for treatment of diseases such as cancers associated with overexpression of EGFR are provided.

Oligonucleotide Inhibition Of Epidermal Growth Factor Receptor Expression

US Patent:

6187585, Feb 13, 2001

Filed:

May 7, 1999

Appl. No.:

9/306876

Inventors:

C. Frank Bennett - Carlsbad CA
Allan Lipton - Hershey PA
Lois M. Witters - York Haven PA

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA
The Penn State Research Foundation - University Park PA

International Classification:

C07H 2104, A61K 4800, C12Q 168

US Classification:

435375

Abstract:

Antisense Oligonucleotide Modulation Of Human Her-2 Expression

US Patent:

5968748, Oct 19, 1999

Filed:

Mar 26, 1998

Appl. No.:

9/048804

Inventors:

C. Frank Bennett - Carlsbad CA
Allan Lipton - Hershey PA
Lois M. Witters - York Haven PA

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA
The Penn State Research Foundation - University Park PA

International Classification:

C12Q 168, C12N 1585, C07H 2104

US Classification:

435 6

Abstract:

Compounds, compositions and methods are provided for inhibiting the expression of human HER-2 (also known as c-neu, ErbB-2 and HER-2/neu). The compositions comprise antisense oligonucleoptides targeted to nucleic acids encoding HER-2. Methods of using these oligonucleotides for inhibition of HER-2 expression and for treatment of diseases such as cancers associated with overexpression of HER-2 are provided. Methods of inhibiting other growth factor receptors using antisense oligonucleotides targeted to nucleic acids encoding HER-2 are also provided.

Platelet Derived Cell Growth Factor

US Patent:

4350687, Sep 21, 1982

Filed:

Feb 10, 1980

Appl. No.:

6/234448

Inventors:

Allan Lipton - Hershey PA
Nancy Kepner - Port Royal PA

Assignee:

Research Corporation - New York NY

International Classification:

A61K 3702, C07G 700, C12N 500, C12P 2100

US Classification:

424177

Abstract:

A purified cell growth factor is produced which comprises a substantially purified glycoproteinaceous factor from platelets which has mitogenic activity toward transformed cells, a molecular weight of 3,000-5,000 daltons and a pI of 7. 8-8. 3. The growth factor is stable to treatment with 4M guanidine hydrochloride, and is heat labile when treated at 100. degree. C. for 5 minutes.

Sensitive Detection Of Wild-Type And Mutant Egfr By Specific Elisa Assays In Any Biological Sample

US Patent:

2001004, Nov 29, 2001

Filed:

Mar 12, 2001

Appl. No.:

09/803854

Inventors:

Albert Wong - Philadelphia PA, US
Kim Leitzel - Hummelstown PA, US
David Moscatello - Philadelphia PA, US
Allan Lipton - Hershey PA, US

International Classification:

G01N033/574, G01N033/537

US Classification:

435/007230, 435/007920

Abstract:

The present invention generally relates a method of detecting type III mutant EGF receptor (EGFRvIII) in biological samples, a method of detecting cancers and other diseases in biological samples, and to a method of assessing treatment and selecting therapy for cancer patients.

Mitogenic Spinal Cord Growth Factor

US Patent:

4376071, Mar 8, 1983

Filed:

Aug 21, 1980

Appl. No.:

6/179945

Inventors:

Thomas J. Jennings - Garden City NY
Allan Lipton - Hershey PA

Assignee:

Research Corporation - New York NY

International Classification:

A01N 6302, A61K 3512, C12N 500

US Classification:

260112R

Abstract:

A proteinaceous factor substantially purified from mammalian spinal cord which has mitogenic activity, a molecular weight of about 11,000, a pI of 9. 6 and which is heat and acid labile, is useful for the promotion of growth of cells.